Drug Trial Radar · NCT06975722
A Study to Investigate the Efficacy and Safety of Brivekimig in Adult Participants With Ulcerative Colitis
Last checked: Nov 19, 2026Latest source record: Nov 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
105
Actual
Start
Jul 7, 2025
Primary completion
Dec 17, 2026
Study completion Oct 17, 2029
Sponsor
- Lead sponsor
- SanofiSanofi (SNY)
- Sponsor type
- Industry
- First posted
- May 16, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a phase 2b, randomized, double-blind, 3-arm study for the treatment of Ulcerative Colitis. The primary objective of this study is to assess the efficacy of different doses of SAR442970 compared with placebo in participants with moderate to severe Ulcerative Colitis. The total study duration is up to 168 weeks, with a treatment period of up to 158 weeks including an open-label (OL) long-term extension (LTE) period of up to 104 weeks for eligible participants.
Conditions
- Ulcerative Colitis
Interventions
SAR442970Drug
Route of administration: Subcutaneous
PlaceboDrug
Route of administration: Subcutaneous
Primary outcomes
What the sponsor says the trial is designed to measure.
- Proportion of participants who achieve clinical remission at the end of Week 16 by modified Mayo Score (mMS)Time frame: At Week 16
Locations
61 sites in 12 countries. Site status is shown where the registry gives one.
Investigational Site Number: 8400027
Fairhope, Alabama
Investigational Site Number: 8400009
Escondido, California
Investigational Site Number: 8400006
Lancaster, California
Investigational Site Number: 8400025
Thousand Oaks, California
Investigational Site Number: 8400024
Jacksonville, Florida
Investigational Site Number: 8400003
Lighthouse PT, Florida
Investigational Site Number: 8400001
Miami, Florida
Investigational Site Number: 8400011
Miami, Florida
Investigational Site Number: 8400010
Palmetto Bay, Florida
Investigational Site Number: 8400019
Tampa, Florida
Investigational Site Number: 8400018
Marietta, Georgia
Investigational Site Number: 8400005
Iowa City, Iowa
Investigational Site Number: 8400017
Boston, Massachusetts
Investigational Site Number: 8400014
St Louis, Missouri
Investigational Site Number: 8400029
Queens Village, New York
Investigational Site Number: 8400023
Houston, Texas
Investigational Site Number: 8400007
Ogden, Utah
Investigational Site Number: 0360001
Clayton, Victoria, Australia
Investigational Site Number: 1560001
Hangzhou, China
Investigational Site Number: 1560007
Ningbo, China
Investigational Site Number: 1560004
Huizhou, Ghangdong, China
Investigational Site Number: 1560005
Guangzhou, Guangdong, China
Investigational Site Number: 1560002
Nanjing, Jiangsu, China
Investigational Site Number: 1560008
Suzhou, Jiangsu, China
Investigational Site Number: 1560003
Wuxi, Jiangsu, China
Investigational Site Number: 1560009
Shanghai, Shanghai Municipality, China
Investigational Site Number: 2030001
Brno, JM, Czechia
Investigational Site Number: 2500002
Lille, France
Investigational Site Number: 2500007
Montpellier, France
Investigational Site Number: 2500006
Nice, France
Investigational Site Number: 2500005
Pierre-Bénite, France
Investigational Site Number: 2500001
Saint-Priest-en-Jarez, France
Investigational Site Number: 2760001
Minden, Northwest, Germany
Investigational Site Number: 2760005
Kiel, Schleswig-Holstein, Germany
Investigational Site Number: 3480003
Budapest, Hungary
Investigational Site Number: 3480002
Budapest, Hungary
Investigational Site Number: 3480001
Vác, Hungary
Investigational Site Number: 3920005
Hamamatsu, Japan
Investigational Site Number: 3920003
Hirosaki, Japan
Investigational Site Number: 3920001
Morioka, Japan
Showing 40 of 61 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.